Blog · Mental Health & Wellness

The 2026 ADHD Review: What It Found, and What Changes

By Vitae Team · 2026-10-10

The independent review into mental health conditions, ADHD and autism published its final report this month, and the government responded on 9 October. Its ten recommendations say less about whether ADHD is over-diagnosed than about who performs assessments, what they cost, and whether anyone should have to wait for a diagnosis before getting help.

The independent review into mental health conditions, ADHD and autism published its final report this month, and the government responded on 9 October. Its ten recommendations say less about whether ADHD is over-diagnosed than about who performs assessments, what they cost, and whether anyone should have to wait for a diagnosis before getting help.

TL;DR

• Recorded diagnoses have risen far faster than the condition. Recorded ADHD prevalence among 6 to 11-year-olds grew more than six-fold between 2000 and 2025, while population prevalence looks broadly stable.
• The people coming forward are not less unwell. The review found no fall in severity or impairment among the rising numbers seeking assessment, which counts against one explanation for the rise rather than settling the question.
• On over-diagnosis it says two things. It cannot conclude over-diagnosis is happening at scale, but warns the risk is shifting if trends continue.
• Independent providers carry out most NHS-funded ADHD assessments, according to the review, which reports strong concerns about their consistency and oversight. This concerns NHS-funded work, not all ADHD diagnoses.
• CQC regulation of all assessments is the stated direction, including those people pay for themselves, but the scope, timetable and legal requirements are still being developed. Separately, NHS England will consult on national prices, with payment arrangements intended from April 2027.
• The biggest proposed change is structural: support based on need rather than on holding a diagnosis.

What the Review Found About Diagnosis Rates

The report, chaired by Professor Peter Fonagy with Professors Gillian Baird and Sir Simon Wessely as vice-chairs, separates two things that are usually conflated. One is how many people have ADHD. The other is how many people are recorded as having it.

On the first, the evidence suggests ADHD prevalence in the population "has remained broadly stable or increased only modestly over recent decades." On the second, recorded prevalence has risen steeply: more than six-fold among 6 to 11-year-olds between 2000 and 2025, and roughly fifteen-fold among 12 to 17-year-olds. Recorded autism prevalence rose further still, more than twenty-fold and forty-fold in those same age bands.

Both prevalence conclusions come with a significant caveat the review makes itself: there is no recent England-wide prevalence survey, and the population estimates rest on data about children and young people. No equivalent adult survey has ever been done. Even the review's own figure of around 3.8% ADHD prevalence among 5 to 15-year-olds is described as a rough projection rather than a measured result, which is why one of the ten recommendations is simply to start measuring properly again.

Over-Diagnosis: The Review Says Two Things

Coverage of the report split in two directions, and that is because the review itself holds two positions at once. Its wording on the first is careful: "On the basis of evidence available to us we cannot conclude that overdiagnosis is occurring at scale," citing the gaps in prevalence data. It then adds that the balance of risks may be shifting towards misdiagnosis and over-diagnosis if current trends continue.

Reported separately, those two statements produce opposite headlines. Held together, they say something more useful: the evidence does not support the claim that large numbers of people have been wrongly diagnosed, and the system as currently built could start producing that problem.

One finding deserved more attention than it got. The review reports that "the rising numbers coming forward for assessment have not been accompanied by any fall in severity or impairment." If the surge were driven mainly by people with milder difficulties, average severity among those presenting should have dropped, and it has not. That counts against one common explanation for the rise. It does not by itself establish that over-diagnosis is absent, since the severity of people presenting for assessment and the accuracy of the diagnoses that follow are different questions.

It is also worth correcting one thing that appeared in coverage. At least one outlet reported the review as blaming the rise in ADHD diagnoses on benefit claims. The report does not say that. It observes that diagnosis has become a requirement for support in parts of the welfare system, and notes that the same evidence gets read differently in the welfare debate, but it does not attribute the growth in diagnoses to welfare claims.

The Waiting Lists, and What Waiting Does

The scale of the backlog is the practical context for everything else. The review reports ADHD referrals rising from around 5,000 a month in 2019 to about 17,000 in 2024, with open referrals passing 560,000 by the end of 2025 — more than seventeen times the 2019 level. It puts community paediatric waiting lists, mostly though not wholly for ADHD assessment, at roughly 173,000. On the autism side, it records more than 254,000 open referrals by December 2025, over 90% of them waiting longer than 13 weeks.

The review attributes this to "not only rising need but a system unable to keep pace with demand," which is a different diagnosis from either over-referral or an epidemic.

What makes the waiting a clinical problem rather than an administrative one is a figure buried in the evidence. Citing national evidence, the review reports that the proportion of people whose difficulties worsened while waiting rose from around one in four of those waiting under two weeks to more than seven in ten of those waiting over six months. It also notes that children diagnosed with ADHD before 17 are around four times more likely to end up not in education, employment or training in early adulthood.

The Private Assessment Market Is Being Regulated

This is the part of the report most likely to change what readers encounter, and it has had the least coverage. The review reports that independent providers carry out more than half of NHS-funded ADHD assessments and more than a third of NHS-funded autism assessments. That is a statement about NHS-commissioned work rather than about ADHD diagnosis generally, and it means the NHS currently meets most of this demand through the independent sector.

It reports "strong concerns" about the consistency and quality of those assessments, and says commissioners "often cannot see what they are paying for." On cost, it puts the rise in independent-sector ADHD spending at around 252% over three years, with a projected overspend of £164 million across the areas it analysed — a projection for those areas rather than a national total, and the report does not specify how many areas that covers. The review is explicit that none of this is a criticism of independent provision in principle, only that its growth has outpaced quality assurance and oversight.

Its fifth recommendation proposes overhauling commissioning, funding, oversight and regulation together. Under it, all ADHD and autism diagnostic assessments would become a CQC-regulated activity, direct-to-public advertising of NHS-funded assessments would be banned, and commissioning would move towards outcome-based integrated services. These are recommendations rather than requirements, and none of them is yet in force. The Health Secretary, Yvette Cooper, framed regulation partly in financial terms, saying it would ensure the NHS "is not being overcharged by independent or private providers."

From Diagnosis-Gated to Needs-Led

The review's most far-reaching idea is not about ADHD specifically. It is that the system has made a diagnosis the price of admission to help. Fonagy's phrasing is blunt: "the system asks people to qualify for help rather than simply giving it to them."

Recommendation 2 proposes shifting from a diagnosis-dependent system to what the report calls needs-led plus diagnosis, organised around a principle of "no wrong front door" and a shared needs assessment framework. It includes a clinically led review of ADHD and autism waiting lists, with a condition attached that nobody should be removed from a list without being connected to appropriate help — which matters, because waiting-list reviews are otherwise an obvious way to make numbers fall without anyone getting treated.

Fonagy has been careful about what this does not mean. Diagnosis, he said, "remains essential and must be protected," but it "is no longer the only door through which help can be reached." The review also cautions against assuming every difficulty needs a medical response, and separately recommends expanding NICE-recommended interventions while strengthening and standardising medication reviews and safe deprescribing.

What the Government Committed To

The response published on 9 October accepts the direction but not every specific. The gap between what was recommended and what was promised is worth reading closely.

The advertising line is the clearest divergence: a recommended ban became a request for a review. The language elsewhere is tentative — "working towards," "exploring" — and no funding figures are attached to the ADHD and autism measures. The review's authors noted they did not know how much investment their recommendations would require, because they were not asked to examine costs. A cross-government mental health strategy is promised in the coming months.

What This Actually Means

If you are waiting for an ADHD assessment, nothing in this changes your position this month. CQC regulation is at the "working towards" stage with no confirmed scope or start date, and the April 2027 date attaches to proposed NHS payment arrangements rather than to regulation. What has changed is the direction of travel, and it points at the assessment market rather than at patients.

For anyone considering a private or Right to Choose assessment, the useful takeaway is that provider quality is now officially an open question rather than a safe assumption. The review did not find that private assessments are unreliable; it found that nobody is systematically checking, and that spending has grown faster than oversight. Until CQC regulation arrives, asking a provider about their assessment process, who conducts it and what happens afterwards is a reasonable thing to do.

The wider argument is the one worth holding onto. Recorded diagnoses have risen many times faster than the best available estimates of the condition itself, the people presenting are no less impaired than before, and many deteriorate while they wait. That combination fits poorly with an epidemic of ADHD and poorly with a fashion for being diagnosed. A capacity problem explains more of it than either, though the review is clear that the prevalence data needed to settle the question does not currently exist.

FAQ

Did the review find that ADHD is over-diagnosed?

No. It said it could not conclude over-diagnosis is occurring at scale, citing gaps in prevalence data, while warning that the risk of misdiagnosis and over-diagnosis may be increasing if current trends continue. Those are two different claims and both appear in the report.

Did it blame the rise on benefits?

No, despite some coverage saying so. The review notes that diagnosis has become a requirement for support in parts of the welfare system, but it does not attribute the growth in diagnoses to welfare claims.

Will private ADHD assessments be regulated?

That is the stated direction. The government says it is working towards making all ADHD and autism diagnostic assessments a CQC-regulated activity, including for people paying for themselves. No date has been set.

Will Right to Choose still exist?

Nothing in the review or the response removes it. What is proposed is regulation and oversight of the providers delivering those assessments, plus national pricing for NHS-funded work from April 2027.

Does this mean I can get help without a diagnosis?

That is the intention behind the review's second recommendation, which proposes a needs-led system where support does not depend on holding a diagnosis. It is a recommendation, not yet a service you can access.

The Bottom Line

The review does not answer the over-diagnosis question. It says the evidence available cannot establish whether over-diagnosis is happening at scale, warns the risk may be growing, and calls for the prevalence surveys that would allow a real answer.

What it proposes to change is the machinery: regulating who assesses, standardising what NHS-funded assessment costs, and uncoupling help from diagnosis. Those are recommendations, and most are some way from reaching anyone waiting today.

This article is for general information and is not a substitute for individual medical advice. If you think you or your child may have ADHD, speak to your GP about assessment routes available in your area.

For a broader, structured approach to the habits that support long-term health, explore the Vitae Reset guides and pair your plan with the Reset Companion for day-to-day support.

Sources

• Fonagy P, Baird G, Wessely S, et al. Independent review into prevalence and support for mental health conditions, ADHD and autism: final report. October 2026. gov.uk
• Department of Health and Social Care. Government pledges earlier support to tackle mental health crises. 9 October 2026. gov.uk
• NHS England. Report of the independent ADHD taskforce. england.nhs.uk
• National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline NG87. nice.org.uk/guidance/ng87